Chronic Myelogenous Leukemia Therapeutics Market by Product and Geography - Global Forecast and Analysis 2019-2023
SKU ID : TNV-14620377 | Publishing Date : 28-Aug-2019 | No. of pages : 157
Detailed TOC of Chronic Myelogenous Leukemia Therapeutics Market by Product and Geography - Global Forecast and Analysis 2019-2023
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Targeted therapy - Market size and forecast 2018-2023
• Chemotherapy - Market size and forecast 2018-2023
• Immunotherapy - Market size and forecast 2018-2023
• Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America - Market size and forecast 2018-2023
• Europe - Market size and forecast 2018-2023
• Asia - Market size and forecast 2018-2023
• ROW - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 10: MARKET TRENDS
• Emergence of pipeline molecules
• Development of diagnostic tests and predictive markers
• Increasing research in regenerative medicines
PART 11: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 12: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Co.
• F. Hoffmann-La Roche Ltd.
• Merck & Co. Inc.
• Mylan NV
• Novartis AG
• Otsuka Holdings Co. Ltd.
• Pfizer Inc.
• Takeda Pharmaceutical Co. Ltd.
• Teva Pharmaceutical Industries Ltd.
PART 13: APPENDIX
• Research methodology
• List of abbreviations
• Definition of market positioning of vendors
PART 14: EXPLORE TECHNAVIO
Exhibit 01: Vendors: Key offerings
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Targeted therapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Targeted therapy - Year-over-year growth 2019-2023 (%)
Exhibit 22: Chemotherapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Chemotherapy - Year-over-year growth 2019-2023 (%)
Exhibit 24: Immunotherapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Immunotherapy - Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by product
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in North America
Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in Europe
Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in Asia
Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 40: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 41: Top 3 countries in ROW
Exhibit 42: Key leading countries
Exhibit 43: Market opportunity
Exhibit 44: Impact of drivers and challenges
Exhibit 45: Vendor landscape
Exhibit 46: Landscape disruption
Exhibit 47: Vendors covered
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: Boehringer Ingelheim International GmbH - Vendor overview
Exhibit 51: Boehringer Ingelheim International GmbH - Product segments
Exhibit 52: Boehringer Ingelheim International GmbH - Organizational developments
Exhibit 53: Boehringer Ingelheim International GmbH - Geographic focus
Exhibit 54: Boehringer Ingelheim International GmbH - Segment focus
Exhibit 55: Boehringer Ingelheim International GmbH - Key offerings
Exhibit 56: Boehringer Ingelheim International GmbH - Key customers
Exhibit 57: Bristol-Myers Squibb Co. - Vendor overview
Exhibit 58: Bristol-Myers Squibb Co. - Product segments
Exhibit 59: Bristol-Myers Squibb Co. - Organizational developments
Exhibit 60: Bristol-Myers Squibb Co. - Geographic focus
Exhibit 61: Bristol-Myers Squibb Co. - Key offerings
Exhibit 62: Bristol-Myers Squibb Co. - Key customers
Exhibit 63: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 64: F. Hoffmann-La Roche Ltd. - Product segments
Exhibit 65: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 66: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 67: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 68: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 69: F. Hoffmann-La Roche Ltd. - Key customers
Exhibit 70: Merck & Co. Inc. - Vendor overview
Exhibit 71: Merck & Co. Inc. - Product segments
Exhibit 72: Merck & Co. Inc. - Organizational developments
Exhibit 73: Merck & Co. Inc. - Geographic focus
Exhibit 74: Merck & Co. Inc. - Segment focus
Exhibit 75: Merck & Co. Inc. - Key offerings
Exhibit 76: Merck & Co. Inc. - Key customers
Exhibit 77: Mylan NV - Vendor overview
Exhibit 78: Mylan NV - Product segments
Exhibit 79: Mylan NV - Organizational developments
Exhibit 80: Mylan NV - Geographic focus
Exhibit 81: Mylan NV - Segment focus
Exhibit 82: Mylan NV - Key offerings
Exhibit 83: Mylan NV - Key customers
Exhibit 84: Novartis AG - Vendor overview
Exhibit 85: Novartis AG - Product segments
Exhibit 86: Novartis AG - Organizational developments
Exhibit 87: Novartis AG - Geographic focus
Exhibit 88: Novartis AG - Segment focus
Exhibit 89: Novartis AG - Key offerings
Exhibit 90: Novartis AG - Key customers
Exhibit 91: Otsuka Holdings Co. Ltd. - Vendor overview
Exhibit 92: Otsuka Holdings Co. Ltd. - Product segments
Exhibit 93: Otsuka Holdings Co. Ltd. - Organizational developments
Exhibit 94: Otsuka Holdings Co. Ltd. - Geographic focus
Exhibit 95: Otsuka Holdings Co. Ltd. - Segment focus
Exhibit 96: Otsuka Holdings Co. Ltd. - Key offerings
Exhibit 97: Otsuka Holdings Co. Ltd. - Key customers
Exhibit 98: Pfizer Inc. - Vendor overview
Exhibit 99: Pfizer Inc. - Product segments
Exhibit 100: Pfizer Inc. - Organizational developments
Exhibit 101: Pfizer Inc. - Geographic focus
Exhibit 102: Pfizer Inc. - Segment focus
Exhibit 103: Pfizer Inc. - Key offerings
Exhibit 104: Pfizer Inc. - Key customers
Exhibit 105: Takeda Pharmaceutical Co. Ltd. - Vendor overview
Exhibit 106: Takeda Pharmaceutical Co. Ltd. - Product segments
Exhibit 107: Takeda Pharmaceutical Co. Ltd. - Organizational developments
Exhibit 108: Takeda Pharmaceutical Co. Ltd. - Geographic focus
Exhibit 109: Takeda Pharmaceutical Co. Ltd. - Key offerings
Exhibit 110: Takeda Pharmaceutical Co. Ltd. - Key customers
Exhibit 111: Teva Pharmaceutical Industries Ltd. - Vendor overview
Exhibit 112: Teva Pharmaceutical Industries Ltd. - Product segments
Exhibit 113: Teva Pharmaceutical Industries Ltd. - Organizational developments
Exhibit 114: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibit 115 Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 116: Teva Pharmaceutical Industries Ltd. - Key customers
Exhibit 117: Validation techniques employed for market sizing
Exhibit 118: Definition of market positioning of vendors